Table 2.
Univariate and Multivariable Analysis for overall survival of the Primary Cohort
|
Variable |
Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| Gender | |||||
| Male/ Female | 0.886(0.508~1.546) | 0.670 | |||
| Age(years) | |||||
| ≤45/>45 | 2.607(1.566~4.342) | <0.001 | 1.765(1.008~3.090) | 0.047 | |
| Tumor stage | |||||
| T1/T2/T3/T4 | 1.613(1.184~2.200) | 0.002 | 0.943(0.623~1.429) | 0.783 | |
| Node stage | |||||
| N0/N1/N2/N3 | 1.858(1.399~2.468) | <0.001 | 1.176(0.849~1.628) | 0.330 | |
| TNM stage | |||||
| I/II/III/IV | 3.083(1.999~4.756) | <0.001 | 1.899(1.023~3.525) | 0.042 | |
| Treatment | |||||
| Radiotherapy/ Chemoradiotherapy | 2.090(0.842~5.188) | 0.112 | |||
| EBVDNA, copy/mL | |||||
| <103/103~9999/104~99999/105~99999/≥106 | 1.674(1.409~1.988) | <0.001 | 1.322(1.087~1.607) | 0.005 | |
| VCA-IgA | |||||
| <1:80/1:80-1:320/≥ 1:640 | 1.624(1.109~2.378) | 0.013 | 0.966(0.576~1.620) | 0.895 | |
| EA-IgA | |||||
| <1:10/1:10-1:20/≥1:40 | 1.486(1.100~2.009) | 0.010 | 1.055(0.714~1.558) | 0.788 | |
| LDH, U/L | |||||
| ≤161.6/>161.6 | 2.594(1.558~4.319) | <0.001 | 1.784(1.032~3.086) | 0.038 | |
| hs-CRP, mg/L | |||||
| ≤2.03/>2.03 | 3.451(2.019~5.899) | <0.001 | 1.840(1.039~3.258) | 0.037 | |
| ALB, g/L | |||||
| ≤43.4/>43.4 | 0.603(0.376~0.968) | 0.036 | 1.235(0.739~2.062) | 0.421 | |
| HLD-C, mmol/L | |||||
| ≤1.17/>1.17 | 0.446(0.271~0.734) | 0.001 | 0.503(0.282~0.896) | 0.020 | |
| APOPA1, g/L | |||||
| ≤1.28/>1.28 | 0.613(0.381~0.988) | 0.044 | 0.862(0.488~1.521) | 0.607 | |
| HGB, g/L | |||||
| ≤139/>139 | 0.416(0.252~0.688) | 0.001 | 0.539(0.309~0.939) | 0.029 | |
| PLR | |||||
| ≤141.08/>141.08 | 1.674(1.036~2.703) | 0.035 | 1.265(0.706~2.265) | 0.430 | |
| NLR | |||||
| ≤2.60/>2.60 | 1.805(1.114~2.926) | 0.016 | 0.839(0.455~1.547) | 0.574 | |
| LMR | |||||
| ≤3.67/>3.67 | 0.374(0.223~0.627) | <0.001 | 0.531(0.293~0.962) | 0.037 | |